Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Stuart H Isaacson, Alyssa Bowling, Ian Zhang, Eric Pappert & Fabrizio Stocchi. (2023) Motor Response With Apomorphine Sublingual Film and Levodopa in Patients With OFF Episodes. Neurodegenerative Disease Management 13:2, pages 75-84.
Read now
Read now
Articles from other publishers (13)
Jan Kassubek, Stewart A. Factor, Ernest Balaguer, Johannes Schwarz, K. Ray Chaudhuri, Stuart H. Isaacson, Stacy Wu, Carmen Denecke Muhr & Jaime Kulisevsky. (2024) Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study. Journal of Neurology.
Crossref
Crossref
Xingzhi Guo, Peng Tang, Xin Zhang & Rui Li. (2024) Revisiting the Effect of Leptin on Alzheimer Disease and Parkinson Disease: The Role of Insulin Sensitivity. The Journal of Clinical Endocrinology & Metabolism.
Crossref
Crossref
Stuart Isaacson, Oliver Phillips & Joohi Jimenez-Shahed. (2024) Hope vs. Hype III: Rescue/on-demand therapies are preferable to device-assisted therapies in Parkinson disease. Parkinsonism & Related Disorders, pages 106079.
Crossref
Crossref
Suresh Thirunavukarasu, Balasubramanian Bala Venkata Ramanan, Sathya Krishnan Suresh, Vincent Jayakumar Antonisamy, Devi Varadharaj, Paranjothi Shanmugam, Kavita Verma, Canmany Elumalai, Gladson Selvakumar, Ahila Elumalai, Lydia Prabahar, Hridwik Adiyeri Janardhanan & Anoop UR. (2023) The Administration of Levodopa in a Patient With Parkinson’s Disease Using a Novel Maxillofacial Route: A First-in-Human Report. Cureus.
Crossref
Crossref
Robert A. Hauser, Alberto J. Espay, Aaron L. Ellenbogen, Hubert H. Fernandez, Stuart H. Isaacson, Peter A. LeWitt, William G. Ondo, Rajesh Pahwa, Johannes Schwarz, Fabrizio Stocchi, Leonid Zeitlin, Ghazal Banisadr, Stanley Fisher, Hester Visser & Richard D’Souza. (2023) IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease. JAMA Neurology 80:10, pages 1062.
Crossref
Crossref
Rajesh Pahwa, Fernando L. Pagan, Daniel E. Kremens & Marie Saint-Hilaire. (2023) Clinical Use of On-Demand Therapies for Patients with Parkinson’s Disease and OFF Periods. Neurology and Therapy 12:4, pages 1033-1049.
Crossref
Crossref
Wolfgang H. Jost, Jaime Kulisevsky & Peter A. LeWitt. (2023) Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease. Journal of Neural Transmission 130:6, pages 821-826.
Crossref
Crossref
Xiao-Zhong Jing, Hui-Jia Yang, Reyisha Taximaimaiti & Xiao-Ping Wang. (2023) Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the
Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease. Current Neuropharmacology 21:5, pages 1224-1240.
Crossref
Crossref
Hussaini Adam, Subash C. B. Gopinath, M. K. Md Arshad, Tijjani Adam, N. A. Parmin, Irzaman Husein & Uda Hashim. (2023) An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment. 3 Biotech 13:5.
Crossref
Crossref
Stuart H. Isaacson, Madhureeta Achari, Roongroj Bhidayasiri, Cynthia Comella, Jill Giordano Farmer, Fiona Gupta, Sarah Jones, David Kreitzman, Daniel Kremens, Simon J.G. Lewis, Werner Poewe, Eduardo Tolosa, Cynthia Campos, Sarah N. Gibbs & Michael S. Broder. (2023)
Expert Consensus on the Use of
On
‐Demand
Treatments for
OFF
Episodes in Parkinson's Disease: A Modified Delphi Panel
. Movement Disorders Clinical Practice 10:4, pages 652-657.
Crossref
Crossref
Philippe Damier, Emily J. Henderson, Jesús Romero-Imbroda, Laura Galimam, Nick Kronfeld & Tobias Warnecke. (2022) Impact of Off-Time on Quality of Life in Parkinson’s Patients and Their Caregivers: Insights from Social Media. Parkinson's Disease 2022, pages 1-11.
Crossref
Crossref
Hazhir Teymourian, Farshad Tehrani, Katherine Longardner, Kuldeep Mahato, Tatiana Podhajny, Jong-Min Moon, Yugender Goud Kotagiri, Juliane R. Sempionatto, Irene Litvan & Joseph Wang. (2022) Closing the loop for patients with Parkinson disease: where are we?. Nature Reviews Neurology 18:8, pages 497-507.
Crossref
Crossref
Shima Kouhnavardi, Alev Ecevitoglu, Vladimir Dragačević, Fabrizio Sanna, Edgar Arias-Sandoval, Predrag Kalaba, Michael Kirchhofer, Jana Lubec, Marco Niello, Marion Holy, Martin Zehl, Matthias Pillwein, Judith Wackerlig, Rita Murau, Andrea Mohrmann, Kathryn R. Beard, Harald H. Sitte, Ernst Urban, Claudia Sagheddu, Marco Pistis, Roberto Plasenzotti, John D. Salamone, Thierry Langer, Gert Lubec & Francisco J. Monje. (2022) A Novel and Selective Dopamine Transporter Inhibitor, (S)-MK-26, Promotes Hippocampal Synaptic Plasticity and Restores Effort-Related Motivational Dysfunctions. Biomolecules 12:7, pages 881.
Crossref
Crossref